

PMD Device Solutions begins preparation for first German hospital pilot

A leading 1,100-bed hospital in Bavaria commences IT governance ahead of their first patient use of RespiraSense in their 30-bed respiratory ward.

A leading 1,100-bed German clinic in the Bavarian region will pilot RespiraSense to address the clinical need for quality respiratory rate monitoring and improving outcomes of non-invasively ventilated patients. This pilot marks the start of PMDS' German market access programme. The pilot process has begun with the review of PMDS' IT (Information Technology) and clinical governance documentation, which will last between 2-3 weeks. After that, the clinical team can use RespiraSense on their first patient in a 30-bed general ward for patients admitted with respiratory compromise. The pilot is anticipated to last for a total of 4 weeks and to commence by late April 2024.

"Over the coming months, PMDS will increase its understanding of hospital requirements to be able to sell in the German market successfully. Such elements include understanding the level of IT governance, clinical workflow, guidance, and the procurement process. These elements are required to ensure an efficient selling process is achieved in any new clinical pathway or geographical market." Says Myles Murray, Founder and CEO of PMDS.

This pilot marks the first of PMDS' financial target to complete more than 10 pilots across the UK, German and US markets during 2024.

Information about PMDS

PMD Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital and homecare setting. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company's shares are listed on Nasdaq First North Growth Market (STO: PMDS).

For additional information, please contact

Myles Murray, CEO

Phone: +353 86 887 4994

E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com

The Company's Certified Adviser is Redeye.



PRESS RELEASE
25 March 2024 11:43:00 CET

Attachments

PMD Device Solutions begins preparation for first German hospital pilot